Cumberland Pharmaceuticals (CPIX) Liabilities from Discontinued Operations (2019 - 2026)
Cumberland Pharmaceuticals (CPIX) posted Liabilities from Discontinued Operations of 1247011.0 for Q1 2020, down 42.04% sequentially from 2151357.0 in Q4 2019.
Cumberland Pharmaceuticals (CPIX) Liabilities from Discontinued Operations (2019 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has reported Liabilities from Discontinued Operations for 2 years, with the latest figure at 1247011.0 in Q1 2020.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 1247011.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was 1247011.0 (changed N/A YoY) and the FY2019 annual result came in at 2151357.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations retreated to 1247011.0 in Q1 2020 per CPIX's latest filing, from 2151357.0 in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at 2151357.0 in Q4 2019 and troughed at 1247011.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Cumberland Pharmaceuticals | 114.68 Mn | 110.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.39 Mn |
| Jun 30, 2026 | 2.39 Mn |
| Dec 31, 2025 | 2.20 Mn |
| Dec 31, 2025 | 2.20 Mn |
| Mar 31, 2020 | 1.25 Mn |
| Mar 31, 2020 | 1.25 Mn |
| Dec 31, 2019 | 2.15 Mn |
| Dec 31, 2019 | 2.15 Mn |